Zhejiang Haisen Pharmaceutical Co Ltd banner
Z

Zhejiang Haisen Pharmaceutical Co Ltd
SZSE:001367

Watchlist Manager
Zhejiang Haisen Pharmaceutical Co Ltd
SZSE:001367
Watchlist
Price: 25.92 CNY -1.89%
Market Cap: ¥3.9B

Multiples-Based Value

The Multiples-Based Value of one Zhejiang Haisen Pharmaceutical Co Ltd stock under the Base Case scenario is 20.58 CNY. Compared to the current market price of 25.92 CNY, Zhejiang Haisen Pharmaceutical Co Ltd is Overvalued by 21%.

Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Multiples-Based Value
20.58 CNY
Overvaluation 21%
Multiples-Based Value
Price ¥25.92
Z
Worst Case
Base Case
Best Case

Multiples Across Competitors

Competitors Multiples
Zhejiang Haisen Pharmaceutical Co Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CN
Zhejiang Haisen Pharmaceutical Co Ltd
SZSE:001367
3.9B CNY 7.7 31.8 23 23
US
Eli Lilly and Co
NYSE:LLY
855.1B USD 13.1 41.4 28 29.9
US
Johnson & Johnson
NYSE:JNJ
574.7B USD 6.1 21.4 14.9 18.3
CH
Roche Holding AG
SIX:ROG
248.4B CHF 4.1 19.7 11.6 13.1
UK
AstraZeneca PLC
LSE:AZN
229B GBP 5.2 29.7 16.4 23.1
US
Merck & Co Inc
NYSE:MRK
291.8B USD 4.5 16 9.9 12.1
CH
Novartis AG
SIX:NOVN
230.8B CHF 5.1 20.5 12.7 16.3
IE
Endo International PLC
LSE:0Y5F
244.4B USD 105.4 -83.6 386.8 970
DK
Novo Nordisk A/S
CSE:NOVO B
1.1T DKK 3.6 11 8.1 9.5
US
Pfizer Inc
NYSE:PFE
154.6B USD 2.5 19.9 7.7 10.2
UK
GSK plc
XETRA:GS71
99.8B EUR 2.7 15.2 8.2 10.2
P/E Multiple
Earnings Growth PEG
CN
Z
Zhejiang Haisen Pharmaceutical Co Ltd
SZSE:001367
Average P/E: 22.6
31.8
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
41.4
31%
1.3
US
Johnson & Johnson
NYSE:JNJ
21.4
8%
2.7
CH
Roche Holding AG
SIX:ROG
19.7
14%
1.4
UK
AstraZeneca PLC
LSE:AZN
29.7
25%
1.2
US
Merck & Co Inc
NYSE:MRK
16
14%
1.1
CH
Novartis AG
SIX:NOVN
20.5
14%
1.5
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -83.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
11
0%
N/A
US
Pfizer Inc
NYSE:PFE
19.9
22%
0.9
UK
GSK plc
XETRA:GS71
15.2
14%
1.1
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CN
Z
Zhejiang Haisen Pharmaceutical Co Ltd
SZSE:001367
Average EV/EBITDA: 47.9
23
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
28
21%
1.3
US
Johnson & Johnson
NYSE:JNJ
14.9
2%
7.5
CH
Roche Holding AG
SIX:ROG
11.6
6%
1.9
UK
AstraZeneca PLC
LSE:AZN
16.4
12%
1.4
US
Merck & Co Inc
NYSE:MRK
9.9
4%
2.5
CH
Novartis AG
SIX:NOVN
12.7
5%
2.5
IE
E
Endo International PLC
LSE:0Y5F
386.8
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
8.1
2%
4
US
Pfizer Inc
NYSE:PFE
7.7
-8%
N/A
UK
GSK plc
XETRA:GS71
8.2
3%
2.7
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett